Inactive Instrument

Genmab Stock Nasdaq Copenhagen

Equities

DK0010272202

Biotechnology & Medical Research

Delayed Nasdaq Copenhagen 11:10:00 2019-07-23 am EDT 5-day change 1st Jan Change
1,217 DKK -0.33% Intraday chart for Genmab +4.14% +14.24%
Sales 2024 * 19.63B 2.8B Sales 2025 * 23.5B 3.35B Capitalization 134B 19.06B
Net income 2024 * 5.07B 723M Net income 2025 * 6.64B 946M EV / Sales 2024 * 5.42 x
Net cash position 2024 * 27.34B 3.9B Net cash position 2025 * 34.53B 4.92B EV / Sales 2025 * 4.22 x
P/E ratio 2024 *
26.3 x
P/E ratio 2025 *
20.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.87%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 63 15-12-31
More insiders
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Calendar
More about the company